In addition to ZYMAR, Allergan’s ACULAR and ALOCRIL continue to perform well in the market. In 2002, ACULAR (ketorolac tromethamine ophthalmic solution 0.5%), prescribed for use before and after cataract and refractive  surgeries, was the No. 1 prescribed ocular non-steroidal anti-inflammatory (NSAID) in the United States and the No. 1 ocular NSAID globally. We are now pleased to offer ACULAR LS (ketorolac tromethamine ophthalmic solution 0.4%). This new, optimized formulation has been approved for the reduction of ocular pain and burning/stinging  following corneal refractive surgery. It joins a family of products used for a range of other conditions, including post- surgical inflammation, pain, photophobia and ocular itch associated with seasonal allergies.  ELESTAT (epinastine HCL ophthalmic solution 0.05%), an ocular anti-histamine with mast cell stabilizing activity, was approved by the FDA in October 2003 for the prevention of itching associated with allergic conjunctivitis. Previously approved in Europe as RELESTAT, this product complements ALOCRIL (nedocromil sodium 2%), a mast cell stabilizer that is currently marketed in the Americas, and fills a gap in Allergan’s portfolio of products in Europe and Asia. In addition, we have entered into a co-promotion agreement in the United States with Inspire Pharmaceuticals, Inc. to broaden the promotion of this drug as our four ophthalmology/optometry sales forces are at full capacity following many recent product approvals.  GLAUCOMA – “LOW ENOUGH” MAY NOT BE GOOD ENOUGH.  Sometimes referred to as the silent thief of sight, glaucoma is the world’s second leading cause of blindness and currently affects more than 60 million people world- wide. Although there is no cure for this progressive disease, early diagnosis and treatment can delay or prevent optic nerve damage and visual field loss. For that reason, eye care professionals see a growing urgency to identify those at risk and treat them more promptly and aggressively. The major risk factor for glaucoma is elevated intraocular pressure (IOP). In the past, some physicians believed that medications on the market brought IOP “low enough.” In 2002, however, the Early Manifest Glaucoma Trial (EMGT) showed that each millimeter of mercury of decreased IOP related to an approximate 10 percent lowering of risk of visual field loss. LUMIGAN (bimatoprost ophthalmic solution 0.03%) is one of the most effective agents for achieving lower IOP currently on the market. Driven by successful launches in North America, Latin America, Europe and the Asian Pacific, LUMIGAN has the potential to be the “best in class” drug to lower IOP as ophthalmologists in clinical practice are increasingly using LUMIGAN. In fact, early in 2004 the European Commission approved LUMIGAN as first-line therapy for the reduction of elevated IOP in chronic open-angle glaucoma and ocular hypertension.  In addition to its use as an adjunctive IOP-lowering agent, the ALPHAGAN franchise (ALPHAGAN brimonidine tartrate ophthalmic solution 0.2% and ALPHAGAN P brimonidine tartrate ophthalmic solution 0.15% preserved with PURITE) is being studied for possible neuroprotective qualities.